| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.96 M USD | 8.56 M USD | -9.56 M USD | -10.43 M USD | -10.89 M USD | -7.32 M USD | -8.15 M USD | -10.84 M USD | -6.47 M USD | -8.41 M USD | -4.46 M USD | -950617 USD |
| Depreciation & Amortization | 24801 USD | 19205 USD | 51798 USD | 41609 USD | 45296 USD | 33399 USD | 51672 USD | 38483 USD | 19288 USD | 5185 USD | 1257 USD | 1724 USD |
| Stock-Based Compensation | 900236 USD | 656593 USD | 754944 USD | 462450 USD | 842475 USD | 723856 USD | 852230 USD | 875287 USD | 870308 USD | 510995 USD | 1.22 M USD | 26815 USD |
| Capital Expenditures | 110789 USD | 6256 USD | 0 USD | 0 USD | 63865 USD | 20077 USD | 0 USD | 20000 USD | 36999 USD | 0 USD | — | — |
| Cash Flow from Investing | 14.43 M USD | -22.66 M USD | 0 USD | 6375 USD | -157020 USD | -244438 USD | 0 USD | -270000 USD | -36999 USD | 174746 USD | -20000 USD | 0 USD |
| Cash Flow from Financing | 265655 USD | 15.50 M USD | 5.97 M USD | 8.62 M USD | 17.80 M USD | 5.00 M USD | 3.92 M USD | 11.30 M USD | 10.67 M USD | 3.50 M USD | 12.62 M USD | 613273 USD |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -10.07 M USD | 8.55 M USD | -9.56 M USD | -10.43 M USD | -10.95 M USD | -7.34 M USD | -8.15 M USD | -10.86 M USD | -6.51 M USD | -8.41 M USD | — | — |
Kiora Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing therapies for eye disease. The company primarily works on innovative treatments aimed at addressing unmet medical needs in ophthalmology. Their research and product development are directed towards advancing therapies that can combat vision-related ailments such as eye inflammation and retinal diseases. By specializing in niche and complex eye conditions, Kiora Pharmaceuticals impacts the biotechnology and healthcare sectors, offering potential breakthroughs and improvements in treatment options. The company's commitment to biotechnology innovation provides vital contributions to therapeutic development within the pharmaceutical landscape, emphasizing targeted, patient-centric approaches in vision care.